Curative effect of iodine-125 brachytherapy and concurrent chemoradiotherapy for middle and advanced stage non-small cell lung cancer / 国际肿瘤学杂志

Objective To review the efficacy and safety of combination of iodine-125 brachytherapy and concurrent chemoradiotherapy for middle and advanced stage non-small cell lung cancer (NSCLC).Methods Eighty-two cases of peripheral NSCLC patients were divided into the experimental group (n =32)and the control group (n =50) by different treatment methods.The patients in experimental group were treated by iodine-125 brachytherapy combined with concurrent chemoradiotherapy,and the patients in control group were treated by concurrent chemoradiotherapy.The two groups were treated with helical tomotherapy,and the chemotherapy regimen was PC regimen (paclitaxel + cisplatin) or TP regimen (taxotere + cisplatin).The response rate (RR),progression free survival (PFS),overall survival (OS) and adverse reactions were observed.Results The RR of experimental group and control group was 87.5％ and 76.0％,and the difference was not statistically significant (x2 =0.992,P =0.319).The median PFS was 16 months and 11 months,and the difference was statistically significant (x2 =5.216,P =0.022).The median OS was 26 months and 19 months,and the difference was not statistically significant (x2 =1.085,P =0.298).There were no statistically significant differences of the occurrence rates of adverse reactions in the experimental group and the control group such as radioactive pneumonia (18.75％ vs.24.00％,x2 =0.314,P =0.575),radiation esophagitis (25.00％ vs.30.00％,x2 =0.242,P =0.623),digestive tract reaction (21.88％ vs.26.00％,x2=0.180,P =0.671),bone marrow suppression (12.50％ vs.16.00％,x2 =0.014,P =0.907) and hemopneumothorax (6.25％ vs.0,P =0.149).Conclusion The combination of iodine-125 brachytherapy with concurrent chemoradiotherapy is a safe and effective treatment for middle and advanced stage NSCLC,which is worthy of further research and promotion.

Study on changes of vascular endothelial cell growth factor in serum with non small cell hung cancer patients before and after radiotherapy / 中国免疫学杂志

Objective:To study the relation between clinical index and prognosis and the level of vascular endothelial cell growth factor(VEGF) in serum of non small cell lung cancer(NSCLC) patients before and after radiotherapy.Methods:VEGF serum of 39 patients with NSCLC and in 20 healthy individuals as control were analyzed with double sandwich in assay ELISA.Results:The level of VEGF serum elevated significantly before radiotherapy in NSCLC patients group as compared with the control(P0 05).And the level gradually declined 0,2～3 months after radiotherapy (P

3-dimensional conformal radiation therapy plus arterial infusion chemotherapy for locally advanced pancreatic cancer / 中华放射肿瘤学杂志

Objective To improve the therapeutic response and survival of locally advanced pancreatic cancer treated with radiochemotherapy. Methods Fifty nine patients with stage Ⅱ Ⅲ pancreatic cancer were divided into two groups: 33 patients were treated with three dimensional conformal radiotherapy (3DCRT) plus regional intra arterial infusion chemotherapy (CT)and 26 patients received 3DCRT alone.Results The response (pain alleviating) rates were 78.8% in 3DCRT+CT group and 80.8% in 3DCRT group,while the overall response (CR+PR) rates were 78.8% and 42.3% (P